Johnson & Johnson
JNJBusiness Overview
ticker: JNJ step: 01 generated: 2026-05-11 source: quick-research
Johnson & Johnson (JNJ) — Business Overview
Business Description
Johnson & Johnson is a fully consolidated pharmaceutical + medical-technology company following the May 2023 separation of its consumer health division (Kenvue, since acquired by Kimberly-Clark for $48.7B announced November 2025). Today's "New J&J" operates two segments: Innovative Medicine (pharmaceuticals, ~64% of revenue) and MedTech (medical devices, ~36%). The company sells globally, with growth led by oncology (Darzalex, Carvykti), immunology (Tremfya replacing Stelara), and cardiovascular medtech (Abiomed, Shockwave). 2026 represents an inflection point as Stelara biosimilar erosion is largely "in the rearview" and the company targets ~$100.5B in 2026 revenue.
Revenue Model
Two segments:
- Innovative Medicine ($60.4B FY25, +6% YoY) — patent-protected branded pharmaceuticals across six therapeutic areas:
- Oncology (~$25B+) — Darzalex (myeloma), Carvykti (CAR-T cell therapy), Erleada (prostate), Rybrevant/Lazcluze (NSCLC), Imbruvica
- Immunology — Tremfya, Stelara (off-patent / biosimilarized), Simponi/Simponi Aria, Remicade
- Neuroscience — Spravato (treatment-resistant depression), Invega (long-acting antipsychotic)
- Cardiovascular / Pulmonary Hypertension — Opsumit, Uptravi, Xarelto (royalty)
- Infectious Diseases — Edurant, Symtuza
- Pulmonary Hypertension — Opsumit
- MedTech ($33.8B FY25, +6%) — medical devices across:
- Surgery (wound closure, biosurgery, surgical vision)
- Cardiovascular (Abiomed Impella, Shockwave intravascular lithotripsy, Biosense Webster electrophysiology)
- Orthopaedics (DePuy Synthes — being spun off / "shrinking to grow faster")
- Vision (contact lenses, IOLs)
Revenue mix is recurring (pharma rx + medtech device + capital equipment), geographically diversified (~50% US, ~50% international).
Products & Services
- Top pharma assets: Darzalex, Carvykti, Tremfya, Erleada, Stelara (eroding), Rybrevant + Lazcluze (NSCLC bispecific combo), Spravato, Imbruvica.
- Pipeline: TAR-200 (intravesical bladder cancer), milvexian (Factor XIa anticoagulant — partnered with BMS), nipocalimab (FcRn for autoimmune), TAR-210, JNJ-2113 (oral IL-23), Tremfya new indications.
- Top medtech franchises: Abiomed (heart pump leadership), Shockwave (IVL), Biosense Webster (electrophysiology), Ethicon (surgical staplers/sutures), Acuvue contact lenses.
- Recent / planned divestitures: Kenvue separation complete (2023); orthopaedics ("DePuy") spin-off announced as part of MedTech reshaping.
Customer Base & Go-to-Market
- Innovative Medicine: hospitals, oncology centers, specialty pharmacies, payers; selling through ~30,000+ sales reps globally.
- MedTech: hospitals, ambulatory surgery centers, physicians; mix of capital equipment + consumables.
- Geographic mix: ~50% US, ~25% Europe, ~25% rest of world.
- No material customer concentration; major risk is payer reimbursement (Medicare Part D negotiation, IRA penalties, ESG drug-pricing pressure).
Competitive Position
J&J is one of the world's largest healthcare companies by revenue and market cap, with the most diversified pharma + medtech franchise of any peer:
- Oncology — Darzalex is the dominant myeloma franchise; Carvykti reaching blockbuster status post-manufacturing expansion.
- Immunology — managing the largest patent-cliff transition in industry history (Stelara → Tremfya + next-gen oral pipeline).
- MedTech — Top 3 in cardiovascular devices (with Medtronic, Abbott); top 3 in surgery (with Medtronic, Stryker).
Structural advantages: (1) AAA credit rating (one of only two non-financial AAAs in US); (2) $100B+ FCF over rolling 5 years to fund R&D + M&A + dividend; (3) 63 consecutive years of dividend increases — Dividend Aristocrat; (4) portfolio diversification — pharma + medtech offset each other's patent cliffs and reimbursement cycles.
Active risks: (1) Stelara biosimilar erosion in immunology (Q4 2025 Stelara sales -49%); (2) talc litigation — 67,000+ ovarian cancer lawsuits unresolved after 3 failed bankruptcy attempts; (3) MedTech China weakness from VBP (volume-based procurement); (4) tariff exposure on imported medical devices.
Key Facts
- Founded: 1886
- Headquarters: New Brunswick, New Jersey
- Employees: ~138,000
- Exchange: NYSE
- Sector / Industry: Health Care / Pharmaceuticals + MedTech
- Market Cap: ~$420B
- Credit Rating: AAA (S&P, one of only 2 non-financial AAAs in US)
- Dividend Aristocrat: 63 consecutive years of increases
- 2025 Revenue: $94.2B
- 2026 Guide: ~$100.5B (+~6%)
Financial Snapshot
ticker: JNJ step: 04 generated: 2026-05-11 source: quick-research
Johnson & Johnson (JNJ) — Financial Snapshot
(FY2023 figures reflect "Old J&J" with Kenvue consumer health; FY2024+ are continuing-operations basis after May 2023 Kenvue separation.)
Income Statement Summary
| Metric | FY2023 | FY2024 | FY2025 | YoY (FY25) |
|---|---|---|---|---|
| Sales (continuing ops basis) | $85.2B | $88.8B | $94.2B | +6.0% |
| Innovative Medicine Revenue | $54.8B | $57.0B | $60.4B | +6.0% |
| MedTech Revenue | $30.4B | $31.9B | $33.8B | +6.1% |
| Adjusted Operational Growth | n/a | n/a | +4.2% | (constant currency, ex-divestitures) |
| GAAP EPS | $7.81 | $5.79 | $11.03 | +90% (vs. one-time charges in FY24) |
| Adjusted EPS | $10.07 | $9.98 | $10.79 | +8.1% |
Segment Detail — Q1 2026 (most recent quarter)
| Asset / Segment | Q1 2026 | YoY |
|---|---|---|
| Darzalex (oncology) | $3.96B | +23% |
| Tremfya (immunology) | $1.61B | +68% |
| Carvykti (CAR-T) | $597M | +62% |
| Stelara (legacy) | -49% (Q4 2025 commentary) | LOE |
| MedTech segment | $8.6B | +8% |
Cash Flow & Balance Sheet (FY2025)
| Metric | Value |
|---|---|
| Operating Cash Flow | ~$25B |
| Capital Expenditures | ~$4.5B |
| Free Cash Flow | $20.4B |
| Dividends Paid | $12.4B (61% payout ratio of FCF) |
| Share Repurchases | ~$1B–3B (variable) |
| Cash & Marketable Securities | ~$22B |
| Total Debt | ~$45B |
| Net Cash Position | ~-$23B (manageable; AAA-rated) |
| Q4 2025 Dividend Hike (Apr 2026) | $1.30 → $1.34 (+3%, 64th consecutive year) |
| FY26 FCF Target | ~$21B |
Key Ratios (approximate)
- P/E: ~17x (FY25 adjusted) | EV/EBITDA: ~13x | FCF Yield: ~4.9%
- Revenue Growth (FY25): +6.0% | FCF Margin: ~22%
- Dividend Yield: ~3.0% | Payout Ratio: ~62% of FCF
- Credit Rating: AAA (one of only 2 non-financial AAAs in US)
- Operating Margin: ~26% (consolidated adjusted)
Growth Profile
2026 marks a key inflection: J&J management explicitly framed the Stelara patent cliff as "in the rearview mirror", freeing growth momentum from oncology + immunology + medtech. Initial 2026 guide of $100.5B in revenue was raised to $100.8B (+7%) on Q1 strength. Key growth drivers in 2026:
- Oncology (Darzalex +23%, Carvykti +62%, Rybrevant/Lazcluze NSCLC ramp)
- Immunology (Tremfya +68% as Stelara replacement; new Icotrokinra oral psoriasis approval)
- MedTech (Abiomed Impella, Shockwave IVL, electrophysiology +mid-teens)
Long-term ambition is $100B+ sales by 2026 (largely achieved) and pathway to ~$120B by 2030 driven by oncology + immunology pipeline (TAR-200, milvexian, nipocalimab, TAR-210).
Forward Estimates
2026 Guide (raised in Q1):
- Reported Sales: $100.8B (+7.0% midpoint)
- Adjusted EPS: $11.55 (+7.1% midpoint)
- FCF target: ~$21B
Bull case: Oncology pipeline drives $25B+ → $35B+ over 5 years; MedTech recovery in China; Carvykti supply catches demand → blockbuster scale; talc litigation finally resolved. Bear case: Stelara erosion accelerates further; talc verdicts exceed reserves (one $1.5B verdict in Dec 2025); MedTech China VBP pressure persists; tariff headwinds on imported devices.
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $JNJ.